Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL779788 | 0.83 | MAPK1 (0.41) | KCNN4LMNATSHRTAAR1NPC1 | |
| SCHEMBL18516974 | 0.83 | HTR2A (0.40) | KCNN4LMNATSHRHTR2AHTR2C | |
| SCHEMBL11229574 | 0.82 | KCNN4 (0.42) | KCNN4LMNATSHRHTR2AHTR2C | |
| SCHEMBL13930866 | 0.82 | KCNN4 (0.42) | KCNN4LMNATSHRHTR2AHTR2C | |
| SCHEMBL6682697 | 0.80 | KCNN4 (0.41) | KCNN4LMNATSHRHTR2AHTR2C | |
| SCHEMBL7414917 | 0.80 | TAAR1 (0.50) | KCNN4LMNATSHRHTR2AHTR2C | |
| SCHEMBL16033653 | 0.80 | KCNN4 (0.41) | KCNN4LMNATSHRHTR2AHTR2C | |
| SCHEMBL6683931 | 0.80 | KCNN4 (0.41) | KCNN4LMNATSHRHTR2AHTR2C | |
| SCHEMBL5925963 | 0.80 | HTR2A (0.41) | KCNN4LMNATSHRHTR2AHTR2C | |
| SCHEMBL574535 | 0.79 | CA2 (0.43) | LMNATSHRHTR2AHTR2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230075221-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVE AND PREPARATION METHOD, HERBICIDAL COMPOSITION AND APPLICATION THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-03-09 | — | — | US | disclosed |
| US-11377422-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11008339-B2 | Substituted pyrazole compounds containing pyrimidine and preparation method and use thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2021-05-18 | — | — | US | disclosed |
| US-10968179-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10842798-B1 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-20200290965-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-10689331-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190002402-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180141961-A1 | Substituted Pyrazole Compounds Containing Pyrimidine and Preparation Method and Use Thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2017-10-05 | — | — | US | disclosed |
| US-9775844-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9751888-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | KCNN4 72/4885LMNA 2685/4885TSHR 4055/4885 |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | KCNN4 3228/4885LMNA 3691/4885TSHR 3798/4885 |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | KCNN4 4545/4885LMNA 966/4885TSHR 4486/4885 |
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, HK1 | KCNN4 4536/4885LMNA 2098/4885TSHR 4772/4885 |
| US-20180141961-A1 | Substituted Pyrazole Compounds Containing Pyrimidine and Preparation Method and Use Thereof | APRT, GART, PNP | KCNN4 2759/4885LMNA 3484/4885TSHR 3754/4885 |
| US-11377422-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | KCNN4 72/4885LMNA 2685/4885TSHR 4055/4885 |
| US-20230075221-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVE AND PREPARATION METHOD, HERBICIDAL COMPOSITION AND APPLICATION THEREOF | TH, CYP4X1, CYP4B1 | KCNN4 205/4885LMNA 3067/4885TSHR 458/4885 |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | KCNN4 3522/4885LMNA 842/4885TSHR 4149/4885 |
| US-20190002402-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | KCNN4 4760/4885LMNA 4498/4885TSHR 4369/4885 |
| US-11008339-B2 | Substituted pyrazole compounds containing pyrimidine and preparation method and use thereof | APRT, GART, PNP | KCNN4 2759/4885LMNA 3484/4885TSHR 3754/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | KCNN4 4545/4885LMNA 966/4885TSHR 4486/4885 |
| US-10842798-B1 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | KCNN4 72/4885LMNA 2685/4885TSHR 4055/4885 |
| US-10968179-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | KCNN4 72/4885LMNA 2685/4885TSHR 4055/4885 |
| US-20200290965-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | KCNN4 72/4885LMNA 2685/4885TSHR 4055/4885 |
| US-10689331-B2 | IDO inhibitors | IDO1, IDO2, INMT | KCNN4 4760/4885LMNA 4498/4885TSHR 4369/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | KCNN4 787/4885LMNA 1463/4885TSHR 586/4885 |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | KCNN4 4119/4885LMNA 1475/4885TSHR 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.